Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Income (2018 - 2025)

Historic Net Income for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.7 million.

  • Whitehawk Therapeutics' Net Income fell 4106.02% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 6725.19%. This contributed to the annual value of -$63.7 million for FY2024, which is 315.37% up from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Net Income stood at -$17.7 million, which was down 4106.02% from -$52.8 million recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Net Income ranged from a high of -$1.5 million in Q2 2021 and a low of -$87.1 million during Q3 2021
  • For the 5-year period, Whitehawk Therapeutics' Net Income averaged around -$20.3 million, with its median value being -$16.0 million (2021).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 291134.16% in 2021, then skyrocketed by 8338.0% in 2022.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Net Income stood at -$16.0 million in 2021, then grew by 12.99% to -$13.9 million in 2022, then dropped by 16.93% to -$16.3 million in 2023, then dropped by 12.32% to -$18.3 million in 2024, then grew by 3.16% to -$17.7 million in 2025.
  • Its last three reported values are -$17.7 million in Q3 2025, -$52.8 million for Q2 2025, and -$14.4 million during Q1 2025.